Biopharma AI
By
Can Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence (AI) and data-driven…
Is Eli Lilly’s $450 Million AI Investment in 2025 Set to Transform Drug Discovery, R&D, and Commercialization?
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence (AI) investments in…
Is Pfizer’s $500 Million AI Investment in 2025 Poised to Redefine Drug Discovery and Commercialization?
Global – December 31, 2025 — Pfizer Inc. significantly increased investment in artificial intelligence (AI) across its discovery,…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
